SCHEDULE: Commodore Capital Discloses 5.5% Passive Stake in Cidara Therapeutics

Commodore Capital LP and its affiliates have reported a passive beneficial ownership of 5.5% of Cidara Therapeutics, Inc.'s common stock.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 1,175,000 shares of Cidara Therapeutics, Inc. common stock.
• This ownership represents 5.5% of the total outstanding common stock of Cidara Therapeutics, Inc.
• The percentage is based on 21,356,877 shares of common stock reported as issued and outstanding in Cidara Therapeutics, Inc.'s Rule 424(b)(5) Prospectus Supplement filed on June 24, 2025.
• The reporting persons hold shared voting and shared dispositive power over all 1,175,000 shares.
• The securities were acquired and are held for investment purposes and not with the intent to change or influence the control of Cidara Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an investment firm is generally a neutral to slightly positive signal, indicating an investor sees value in the company without seeking control.

Positives

• The disclosure of a significant 5.5% stake by an investment firm like Commodore Capital may signal investor confidence in Cidara Therapeutics, Inc.

Future Outlook

No forward-looking statements or guidance from Cidara Therapeutics, Inc. are provided in this beneficial ownership disclosure.

Management Comments

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Cidara Therapeutics, Inc., and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a standard disclosure required when an investor or group acquires beneficial ownership of more than 5% of a company's equity securities, indicating a passive investment position. Such disclosures are common in the biotechnology and pharmaceutical sectors, where investment firms often take positions in companies with promising drug pipelines or technologies.

Stakeholder Impact

• Shareholders: The disclosure of a new significant passive investor may influence investor perception and potentially the stock price, signaling confidence from an institutional investor.

Key Dates

Keywords

Cidara Therapeutics, Commodore Capital, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Passive Stake